Browsing Tag
Ying Huang
3 posts
Legend Biotech names Ingrid Zhang CEO as CARVYKTI sales surge 50%
Legend Biotech Corporation has appointed former Novartis commercial executive Ingrid Zhang as chief executive after a seven-week leadership search, putting an experienced global medicines operator in charge as CARVYKTI sales accelerate and the cell therapy company tries to build its next growth engine.
Legend Biotech (NASDAQ: LEGN) CARVYKTI scaling meets LB2102 solid tumor signal
Legend Biotech (NASDAQ: LEGN) printed 62% CARVYKTI growth and a solid tumor CAR-T signal. The 2026 profitability target is the next real test.
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…